Piramal Pharma Ltd (PPLPHARMA)

📊 Quarterly Results (₹ Cr)

Revenue growth has accelerated, with Q1 FY27 revenue up 17% YoY to ₹2,270 crores, reversing a recent trend of sequential declines seen in prior quarters (e.g., December 2025 revenue of ₹2,140 crores). EBITDA margin expansion to 12.5% from 8.5% indicates successful cost optimization and scale benefits. However, PAT after exceptional items remains negative at ₹(69) crores, though improved 15% YoY, reflecting persistent operational losses despite top-line gains. The company is investing heavily in capacity and acquisitions, which is pressuring near-term profitability but positioning it for long-term margin accretion.

🔮 Management Outlook & What's Next

Management expects sustained revenue growth and EBITDA expansion through FY27, supported by strategic investments and capacity additions. While forward guidance was not explicitly provided in the latest filing, the company highlighted robust order inflows in CDMO, leadership in inhalation anesthesia, and profitable growth in Consumer Healthcare as tailwinds. The integration of Yapan Bio as a subsidiary is expected to strengthen biologic manufacturing capabilities, enabling scalable, high-margin offerings. Management emphasized operational execution and regulatory milestones, including FDA approval, as key enablers of future growth.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

The balance sheet shows a steady increase in total assets, rising to ₹17,965 crores as of March 2026 from ₹15,678 crores in March 2025, driven by asset expansion and investments in subsidiaries like Yapan Bio. Borrowings increased to ₹5,495 crores from ₹4,851 crores, indicating active capital deployment for growth initiatives. Equity and reserves remain stable around ₹8,162 crores, suggesting capital is being raised through debt rather than equity dilution. The company is leveraging debt to fund acquisitions and capacity expansion, consistent with its strategy to scale CDMO operations.

💰 Cash Flow Statement (₹ Cr)

👥 Shareholding Pattern

Institutional investor interest has significantly increased, with FII holdings rising from 29.66% in Q3FY26 to 12.52% in Q1FY27, while DII holdings remained relatively stable around 14.57%. Promoter holding is steady at approximately 34.8%. The growing institutional stake, particularly from FIIs, signals confidence in the company’s turnaround narrative and strategic direction. The rise in shareholder count to 4,61,096 from 4,50,661 in Q4FY26 also reflects broader retail interest and improved market participation.

⚖️ Peer Comparison — Pharmaceuticals

🔗 Peer Stock Analyses

⚠️ Risk Factors

1. Persistent net losses despite revenue growth, with profitability still dependent on margin expansion and cost control. 2. High leverage ratio (D/E of 0.67) combined with aggressive capital deployment could strain financial flexibility if growth slows. 3. Integration risks associated with Yapan Bio acquisition, including operational alignment and realization of synergies. 4. Volatility in PAT due to non-recurring items and foreign exchange fluctuations, as highlighted in past filings, may affect earnings stability.

📋 Recent Filings

• Announcement2026-09-29Piramal Pharma announced that its trading window will close on October 1, 2026, and remain shut for 48 hours after the unaudited half‑year results for…
• 🔴 Corporate Action2026-09-29Piramal Pharma disclosed a GST audit order requiring Rs. 4,06,03,220 in input tax credit demand and penalty for FY 2020-21 to 2022-23, which it plans …
• 🔴 Announcement2026-09-18Piramal Pharma disclosed that an independent ESG rating agency, Niche99, assigned it an ESG score of 67.1, placing it in the 'Leader' band, without an…
• 🔴 Announcement2026-09-14Piramal Pharma disclosed that the US FDA conducted a GMP inspection at its Morpeth, UK facility from September 3-11, 2026, issuing Form 483 with 7 obs…
• 🔴 Announcement2026-09-08Piramal Pharma announced its schedule for upcoming institutional investor meetings in late September 2026, organized by Avendus Spark, with one-on-one…
• 🔴 Announcement2026-09-03Piramal Pharma disclosed that NSE Sustainability Ratings and Analytics assigned an ESG rating of 65 for FY 2025-26, up from 64, reflecting improved su…
• 🔴 Announcement2026-08-18Piramal Pharma announced it completed the acquisition of an additional 40.67% stake in Yapan Bio Private Limited for approximately ₹76 crores, increas…
• 🟡 Board Meeting2026-08-10Piramal Pharma announced it exercised its call option to acquire an additional 41% stake in Yapan Bio Private Limited, increasing its ownership from 3…
• Announcement2026-08-10Piramal Pharma announced its schedule of analyst and institutional investor meetings for September 2026, including events with Elara, Jefferies, Kotak…
• 🔴 Financial Results2026-07-31Piramal Pharma Limited announced the transcript of its conference call discussing unaudited financial results for the quarter ended June 30, 2026, ava…

🧠 Analyst's Read

Piramal Pharma is executing a clear turnaround strategy centered on strategic acquisitions, capacity expansion, and segmental growth, particularly in CDMO and consumer healthcare. While revenue and EBITDA trends are encouraging, profitability remains fragile, and execution risks around integration and margin sustainability persist. Investors should monitor upcoming disclosures on Yapan Bio integration and clarity on FY27 guidance for sustained momentum.

Based on filing content and financial data. Not a recommendation.